Study of Eltrombopag in Platelet Refractory Thrombocytopenia

Status Withdrawn

Clinical Trial Summary

This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia (low platelet count). Eltrombopag is approved by the FDA for the treatment of thrombocytopenia (low platelet count) in adults who have had an insufficient response to medications such as corticosteroids and immunoglobulins. Eltrombopag is not approved by the FDA (Food and Drug Administration) for the treatment of thrombocytopenia refractory to platelet transfusion and so for this study is considered investigational.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Thrombocytopenia

Clinical Trial Details

NCT number	NCT01194167
Study type	Interventional
Source	University of Cincinnati
Contact
Status	Withdrawn
Phase	Phase 2
Start date	August 2010
Completion date	January 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04003220` - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed	`NCT02948283` - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia	Phase 1
Recruiting	`NCT03633019` - High-dose Use of rhTPO in CIT Patients	Phase 4
Recruiting	`NCT06087198` - Clinical Performance Evaluation of T-TAS®01 HD Chip
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Active, not recruiting	`NCT03688191` - Study of Sirolimus in CTD-TP in China	Phase 4
Completed	`NCT02845609` - Efficacy of Sialic Acid GNE Related Thrombocytopenia	Phase 2
Recruiting	`NCT02244658` - Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia	Phase 3
Recruiting	`NCT02241031` - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia	Phase 2/Phase 3
Terminated	`NCT01368211` - Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)	Phase 2/Phase 3
Unknown status	`NCT01196884` - Immune Thrombocytopenia (ITP) Immune-Genetic Assessment
Completed	`NCT01356576` - Effect of Hemodialysis Membranes on Platelet Count	N/A
Completed	`NCT00039858` - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Phase 4
Completed	`NCT00787241` - Platelet Count Trends in Pre-eclamptic Parturients	N/A
Completed	`NCT00001533` - Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine	Phase 1
Not yet recruiting	`NCT06036966` - The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients	Phase 2
Completed	`NCT01791101` - Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.	Phase 2
Recruiting	`NCT06053021` - Antiplatelet Therapy for AIS Patients With Thrombocytopenia	N/A
Recruiting	`NCT03701217` - Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML	Phase 2/Phase 3
Not yet recruiting	`NCT05958511` - Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients